Australia's most trusted
source of pharma news
Tuesday, 10 March 2026
Posted 10 March 2026 PM
Bayer and Teva have lost a stoush challenging Cipla's extension of a patent after a ruling that a failure to pay renewal fees on time was due to a genuine error.
IP Australia delegate Greg Powell said he was satisfied some "breakdown in procedure" had occurred which meant the renewal fees were not paid on time to extend a patent titled Combination of azelastine and steroids, owned by Cipla, according to Australian legal publication, Lawyerly.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.